NCT04236960View on ClinicalTrials.gov

Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 17, 2018

Primary Completion Date

September 16, 2019

Study Completion Date

November 28, 2019

Conditions
Meningococcal Infections
Interventions
BIOLOGICAL

Meningococcal Group ACYW135 Conjugate Vaccine

1 dose in Stage 1 (2\~55 yrs), 2 doses in Stage 2 (7\~23 mos), and 3 doses in Stage 3 (2\&3 mos)

Trial Locations (1)

Unknown

Guangdong Provincial Center for Disease Control and Prevention, Guangzhou

All Listed Sponsors
lead

Walvax Biotechnology Co., Ltd.

INDUSTRY

NCT04236960 - Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population. | Biotech Hunter | Biotech Hunter